Janssen's Novel RSV Fusion Protein Inhibitor JNJ-53718678 Oral Suspension Designated for Breakthrough Therapy in China for Treatment of Moderate to Severe RSV Lower Respiratory Tract Infections in Children

According to the latest public announcement on the website of the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration, JNJ-53718678 oral suspension, developed by Janssen, a subsidiary of Johnson & Johnson, is proposed for inclusion in the Breakthrough Therapy Designation program. The proposed indication is for the treatment of moderate to severe respiratory infections caused by respiratory syncytial virus (RSV) in children. Publicly available information indicates that JNJ-53718678 is a novel human RSV fusion protein inhibitor with potential for treating respiratory syncytial virus infections.

Source: CDE Official Website

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly. In addition to developing preventive vaccines, another R&D strategy for combating RSV-induced diseases is to block the virus from entering respiratory tract cells. The RSV fusion protein is a viral surface glycoprotein that plays a critical role in the fusion of RSV with target cells and subsequent cellular entry. The surface of RSV is enveloped by two glycoproteins: the attachment glycoprotein (G) and the fusion glycoprotein (F). Research has shown that the fusion glycoprotein (F) is essential for RSV entry into cells, making it an ideal target for researchers developing RSV fusion protein inhibitors.

As a novel oral RSV fusion protein inhibitor, JNJ-53718678 specifically targets and binds to the viral surface fusion protein, inhibiting RSV fusion protein-mediated fusion with the host cell membrane and thereby preventing viral entry. This mechanism prevents RSV replication, reduces viral load, and consequently decreases disease severity.

Information on the ClinicalTrials.gov website indicates that Janssen has registered 16 Phase 1 or Phase 2 clinical studies on JNJ-53718678, some of which have been completed. According to the results of a Phase 1 clinical trial conducted in healthy subjects previously released by the company, JNJ-53718678 demonstrated good tolerability.

Currently, Janssen is conducting multiple clinical trials on JNJ-53718678. One of these is a randomized, double-blind, placebo-controlled Phase 2 clinical trial aimed at evaluating the clinical outcomes, antiviral activity, safety, tolerability, pharmacokinetics, and other characteristics of JNJ-53718678 in adult and adolescent hematopoietic stem cell transplant patients with respiratory syncytial virus (RSV) upper respiratory tract infections. In China, a double-blind, placebo-controlled, randomized study assessing the pharmacokinetics, safety, and tolerability of JNJ-53718678 in healthy Chinese adult subjects, involving both single-dose and multiple-dose administrations, is currently ongoing.

▽Follow [WuXi AppTecDe】WeChat Official Account